Sigyn Therapeutics, Inc. (SIGY): R&D Expense
Not updated since 2024-12-31. No annual report in US GAAP has been filed since. Companies that switch to IFRS reporting, as many foreign filers do, or stop filing are not updated here.
$773.3K
Year ended 2024-12-31
$140.1K
Trailing 12 months to 2025-09-30
+1.8%
3-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2024-12-31 | $773.3K | -3.1% | 2025-04-15, From 2024-01-01 |
| 2023-12-31 | $798.2K | +21.4% | 2025-04-15, From 2023-01-01 |
| 2022-12-31 | $657.7K | -10.4% | 2024-02-20, From 2022-01-01 |
| 2021-12-31 | $734.0K | +75.0% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $419.4K | n/a | 2022-03-21, From 2020-01-01 |